Login to Your Account



Pharma: Clinic Roundup


Wednesday, September 18, 2013
• Ipsen SA, of Paris, reported positive top-line findings from the primary endpoint of the ELECT study assessing the effect of Somatuline Autogel/Somatuline Depot (lanreotide) Injection 120 mg in controlling symptoms in patients with neuroendocrine tumors associated with carcinoid syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription